TRIM62 antibody
Principal name
TRIM62 antibody
Alternative names for TRIM62 antibody
Tripartite motif-containing protein 62
Ncbi ID
NP_060677, 9606, NP_060677.2, NM_018207, NP_835211.1, NM_178110
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Enzyme Immunoassay (E), Paraffin Sections (P)
Background of TRIM62 antibody
- Kit Component:
- - KN200126G1, TRIM62 gRNA vector 1 in pCas-Guide vector
- KN200126G2, TRIM62 gRNA vector 2 in pCas-Guide vector
- KN200126D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
General readings
Gregory,S.G., (2006) Nature 441 (7091), 315-321
Human Jurkat; WB Suggested Anti-TRIM62 Antibody Titration: 1.25ug/ml. ELISA Titer: 1:1562500. Positive Control: Jurkat cell lysate; TRIM62 antibody - N-terminal region (ARP39341_T100) in Human Jurkat cells using Western Blot
Western Blot analysis of TRIM62 expression in transfected 293T cell line (H00055223-T02) by TRIM62 MaxPab polyclonal antibody.Lane 1: TRIM62 transfected lysate(54.30 KDa).Lane 2: Non-transfected lysate.
Human 293T; WB Suggested Anti-TRIM62 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: 293T cell lysate; TRIM62 antibody - middle region (ARP39342_P050) in Human 293T cells using Western Blot
Immunofluorescence of purified MaxPab antibody to TRIM62 on HeLa cell. [antibody concentration 10 ug/ml]
TRIM62 MaxPab polyclonal antibody. Western Blot analysis of TRIM62 expression in human spleen.
Western Blot analysis of TRIM62 expression in transfected 293T cell line (H00055223-T01) by TRIM62 MaxPab polyclonal antibody.Lane 1: TRIM62 transfected lysate(52.25 KDa).Lane 2: Non-transfected lysate.
Human Small Intestine; WB Suggested Anti-TRIM62 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:62500. Positive Control: Human Small Intestine; TRIM62 antibody - N-terminal region (ARP34576_P050) in Human Small Intestine cells using Western Blot
WB Suggested Anti-TRIM62 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1:62500; Positive Control: Human Small Intestine
WB Suggested Anti-TRIM62 Antibody Titration: 1.25 ug/ml; ELISA Titer: 1: 1562500; Positive Control: Jurkat cell lysate
WB Suggested Anti-TRIM62 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1: 312500; Positive Control: 293T cell lysate
Gel: 8%SDS-PAGE, Lysate: 40 ug, Lane 1-2: 231 cells, hepg2 cells, Primary antibody: (TRIM62 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using (TRIM62 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: ×200)
The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using (TRIM62 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: ×200)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA351814 | TRIM62 antibody |
||||||
| Rabbit Polyclonal Anti-TRIM62 Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu | E, P, WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
 +2 additional images |
|||||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY413216 | TRIM62 overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR207605L2V | Lenti ORF particles, Trim62 (GFP-tagged) - Mouse tripartite motif-containing 62 (Trim62), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,150.00
|
|
| OriGene Technologies, Inc. | ||
| MR207605L1V | Lenti ORF particles, Trim62 (Myc-DDK-tagged) - Mouse tripartite motif-containing 62 (Trim62), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,030.00
|
|
| OriGene Technologies, Inc. | ||